Evidence map›Paper›PMID 24144909›Full record

ArticleNeuropharmacology2014

Probing the non-canonical interface for agonist interaction with an α5 containing nicotinic acetylcholine receptor.

Christopher B Marotta, Crystal N Dilworth, Henry A Lester, Dennis A Dougherty

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Analogs of α-conotoxin PnIC selectively inhibit α7β2- over α7-only subtype nicotinic acetylcholine receptors via a novel allosteric mechanism.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  3. Article
  4. Concatemers to re-investigate the role of α5 in α4β2 nicotinic receptors.Cellular and molecular life sciences : CMLS · 2021
    Article
  5. The fifth subunit of the (α4β2)British journal of pharmacology · 2018
    Article
  6. Isoform-specific mechanisms of α3β4*-nicotinic acetylcholine receptor modulation by the prototoxin lynx1.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Christopher B MarottaDivision of Chemistry and Chemical Engineering, California Institute of Technology, 1200 E California Blvd., Pasadena, CA 91125, USA.
Crystal N DilworthDivision of Chemistry and Chemical Engineering, California Institute of Technology, 1200 E California Blvd., Pasadena, CA 91125, USA.
Henry A LesterDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Dennis A DoughertyDivision of Chemistry and Chemical Engineering, California Institute of Technology, 1200 E California Blvd., Pasadena, CA 91125, USA. Electronic address: dadougherty@caltech.edu.
California Institute of Technology · US

Funding

PREDOCTORAL TRAINING IN BIOLOGY AND CHEMISTRYT32GM007616 · NIGMS · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI STERNBERG, PAUL WARREN · 1985 to 2019
$22.9M
Alpha4 Nicotinic Receptor in Addiction: Mouse ModelsR01DA017279 · NIDA · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI LESTER, HENRY A. · 2004 to 2014
$3.5M
PROBING RECEPTOR STRUCTURES WITH UNNATURAL AMINO ACIDSR01NS034407 · NINDS · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI DOUGHERTY, DENNIS A · 1995 to 2016
$3.1M
Probing Receptor Structures with Unnatural Amino AcidsR37NS034407 · NINDS · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI DOUGHERTY, DENNIS A · 2004 to 2010
$2.7M
NIDA NIH HHS DA017279NIDA NIH HHS DA280382NIDA NIH HHS R01 DA017279NIGMS NIH HHS GM07616NIGMS NIH HHS T32 GM007616NINDS NIH HHS NS034407NINDS NIH HHS R01 NS034407NINDS NIH HHS R37 NS034407
6 · The paper itself

Abstract

Nicotinic acetylcholine receptors (nAChRs) containing the α5 subunit are of interest because genome-wide association studies and candidate gene studies have identified polymorphisms in the α5 gene that are linked to an increased risk for nicotine dependence, lung cancer, and/or alcohol addiction. To probe the functional impact of an α5 subunit on nAChRs, a method to prepare a homogeneous population of α5-containing receptors must be developed. Here we use a gain of function (9') mutation to isolate populations of α5-containing nAChRs for characterization by electrophysiology. We find that the α5 subunit modulates nAChR rectification when co-assembled with α4 and β2 subunits. We also probe the α5-α4 interface for possible ligand-binding interactions. We find that mutations expected to ablate an agonist-binding site involving the α5 subunit have no impact on receptor function. The most straightforward interpretation of this observation is that agonists do not bind at the α5-α4 interface, in contrast to what has recently been demonstrated for the α4-α4 interface in related receptors. In addition, our mutational results suggest that the α5 subunit does not replace the α4 or β2 subunits and is relegated to occupying only the auxiliary position of the pentameric receptor.

Indexed as

AnimalsBinding SitesNicotineProtein SubunitsReceptors, NicotinicXenopus laevisCHRNA5 protein, mouseNicotineProtein SubunitsReceptors, NicotinicA2B3A3B2AddictionBiophysicscentral nervous systemCholinergic receptorCNSElectrophysiologyhigh sensitivity (α4β2)(2)(β2) receptorHill coefficientIon channelslow sensitivity (α4β2)(2)(α4) receptornAChRnHnicotinic acetylcholine receptorNicotinic acetylcholine receptorsSEMstandard error of the mean

Identifiers

PMID24144909
PMCPMC3934363
OpenAlexW1964937150

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.